CO6771460A2 - Treatment of vaginal atrophy with new indication for myrrh - Google Patents

Treatment of vaginal atrophy with new indication for myrrh

Info

Publication number
CO6771460A2
CO6771460A2 CO13231573A CO13231573A CO6771460A2 CO 6771460 A2 CO6771460 A2 CO 6771460A2 CO 13231573 A CO13231573 A CO 13231573A CO 13231573 A CO13231573 A CO 13231573A CO 6771460 A2 CO6771460 A2 CO 6771460A2
Authority
CO
Colombia
Prior art keywords
treatment
myrrh
vaginal atrophy
new indication
atrophy
Prior art date
Application number
CO13231573A
Other languages
Spanish (es)
Inventor
Eva Brandt
Original Assignee
Sonia Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/050,225 external-priority patent/US8287924B2/en
Priority claimed from EP11158593.1A external-priority patent/EP2500026B1/en
Application filed by Sonia Pharma Gmbh filed Critical Sonia Pharma Gmbh
Publication of CO6771460A2 publication Critical patent/CO6771460A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/32—Burseraceae (Frankincense family)
    • A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)

Abstract

La invención consiste en una nueva indicación para a mirra, concretamente el tratamiento de la atrofia vaginal como síntoma menopáusico. Además, la invención incluye un preparado farmacéutico en forma de dosis vaginal para el tratamiento de dicha atrofia, así como un procedimiento para elaborar un preparado farmacéutico contra la atrofia vaginal como síndrome de la menopausia.The invention consists of a new indication for myrrh, specifically the treatment of vaginal atrophy as a menopausal symptom. In addition, the invention includes a pharmaceutical preparation in the form of a vaginal dose for the treatment of said atrophy, as well as a method for preparing a pharmaceutical preparation against vaginal atrophy as a menopause syndrome.

CO13231573A 2011-03-17 2013-09-30 Treatment of vaginal atrophy with new indication for myrrh CO6771460A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/050,225 US8287924B2 (en) 2011-03-17 2011-03-17 Treatment of menopausal symptoms as novel indication for myrrh
EP11158593.1A EP2500026B1 (en) 2011-03-17 2011-03-17 Treatment of menopausal symptoms as novel indication for myrrh

Publications (1)

Publication Number Publication Date
CO6771460A2 true CO6771460A2 (en) 2013-10-15

Family

ID=45929506

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13231573A CO6771460A2 (en) 2011-03-17 2013-09-30 Treatment of vaginal atrophy with new indication for myrrh

Country Status (8)

Country Link
JP (1) JP5519879B2 (en)
KR (1) KR20130130034A (en)
AU (1) AU2012228213B2 (en)
BR (1) BR112013023092A2 (en)
CA (1) CA2829792C (en)
CO (1) CO6771460A2 (en)
MX (1) MX352788B (en)
WO (1) WO2012123539A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2967506A1 (en) 2016-01-18 2017-07-18 Nadiah Abdulkarim A. Alessa Composition for treatment and preventative of the human papilloma virus hpv infection, ulcerations and boils
CN112236198A (en) * 2018-06-29 2021-01-15 宝洁公司 Vaginal care composition
WO2021123925A1 (en) * 2019-12-15 2021-06-24 Banooye Armaghan Teb Herbal compositions and administration methods for the treatment of infections and inflammation of vulvovaginal and the pelvic organs

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4592912A (en) 1983-10-31 1986-06-03 Harriet Nickolaus Ache and pain relieving and preventing composition
US4719111A (en) 1985-06-14 1988-01-12 Wilson Lynn M Novel composition for treatment of decubitus ulcers
JPS63104924A (en) * 1986-10-20 1988-05-10 Kanebo Ltd Pessary
AU630561B2 (en) 1990-06-12 1992-10-29 Cathy Palou A therapeutic preparation containing myrrh for treating skin disorders
US6350784B1 (en) * 1996-02-12 2002-02-26 Meryl J. Squires Antimicrobial prevention and treatment of human immunedeficiency virus and other infectious diseases
US5248503A (en) 1992-01-03 1993-09-28 Emanuel King Rosalba Herbal dietary supplement
US6077513A (en) 1996-05-02 2000-06-20 Massoud; Ahmed Mohamed Ali Drug for treatment of bilharziasis (Schistosomiasis)
ZA200000192B (en) * 1998-10-30 2000-08-07 Jullienne Jacques Roger Jean M Novel composition.
US6893648B2 (en) 2002-01-04 2005-05-17 Harold Mermelstein Composition and method for treatment of vaginal dryness
CN1559586A (en) * 2004-03-04 2005-01-05 健 曹 External used Chinese patent drug for trenting gynecopathy
CN1679687A (en) 2005-02-02 2005-10-12 姚素英 External-applied capsules for treating gynecopathy and preparation thereof
CN101057892B (en) * 2006-04-19 2010-11-10 河南省宛西制药股份有限公司 Medicinal composition for treating vaginal diseases and its preparation method and application
CN101849981B (en) * 2010-06-22 2011-11-23 南京中医药大学 Myrrh target area for treatment of gynecological tumor and preparation method and application thereof

Also Published As

Publication number Publication date
MX2013010415A (en) 2013-12-02
JP5519879B2 (en) 2014-06-11
AU2012228213B2 (en) 2015-08-06
WO2012123539A1 (en) 2012-09-20
JP2014508158A (en) 2014-04-03
AU2012228213A1 (en) 2013-09-12
CA2829792C (en) 2017-04-04
BR112013023092A2 (en) 2016-12-06
MX352788B (en) 2017-12-05
CA2829792A1 (en) 2012-09-20
KR20130130034A (en) 2013-11-29

Similar Documents

Publication Publication Date Title
CR20150326A (en) AUTOTAXIN INHIBITORS
CR20140231A (en) ACETIC BENZOTIAZOL-6-IL ACID DERIVATIVES AND THEIR USE TO TREAT AN HIV INFECTION
PE20150631A1 (en) CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR
CU20170009A7 (en) 2- (MORFOLIN-4-IL) -1,7-USEFUL NAFTIRIDINS IN THE TREATMENT OR PROFILAXIS OF HYPERPROLIFERATIVE DISEASES
JP2014515038A5 (en)
CL2014001049A1 (en) Compounds derived from substituted purine, mtor inhibitors; pharmaceutical composition; pharmaceutical combination; use for the treatment or prevention of cancer, a neurodegenerative disorder or an ophthalmological disease.
UY34705A (en) MULTIPLE LAYER FILMS ABLE TO RELEASE ACTIVE INGREDIENTS FOR A LIMITED TIME PERIOD
CL2015001610A1 (en) Compounds derived from pyrimido- [4,5-b] -quinoline-4,5 (3h, 10h) -diones to be used as a medicament for the treatment of a disease caused by a nonsense mutation; composition and pharmaceutical combination that includes them.
DOP2017000146A (en) PIRAZOLPIRIDINAMINS AS INHIBITORS OF MKNK1 AND MKNK2
EP3034082A4 (en) Pharmaceutical composition for treating or preventing neuropsychitric disease, containing flavone-6-c-glucose derivatives as active ingredients
PE20142043A1 (en) SELECTIVE METABOLIC APPROACH TO INCREASE ORAL BIOAVAILABILITY OF PHENYLEPHRIN AND OTHER METABOLIC BIOACTIVES
DOP2016000118A (en) TIENOPIRIMIDINS AS MKNK1 AND MKNK2 INHIBITORS
UY34786A (en) PROCEDURE FOR THE MANUFACTURE OF A PHARMACEUTICAL FORM INCLUDING NIFEDIPINO AND CANDESARTAN CILEXETILO
IN2014CH00395A (en)
ES2524385R1 (en) Pharmaceutical composition and its use to prepare a medicine for the treatment and prevention of HIV diseases
PH12016502243A1 (en) Pharmaceutical compositions for treating infectious diseases
PE20150721A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING GEMIGLIPTIN AND METFORMIN, AND METHOD FOR THEIR PREPARATION
ES2415029R1 (en) Pharmaceutical composition and method to inhibit the production or amplify the elimination of the P24 protein.
CO2017007316A2 (en) Pharmaceutical formulation
CL2015002466A1 (en) Organic compound formulations
CO7121334A2 (en) Vesicular formulations
CO6771460A2 (en) Treatment of vaginal atrophy with new indication for myrrh
BR112013019798A2 (en) bakuchiol compositions for treating postinflammatory hyperpigmentation.
AR098614A1 (en) COMPOUND FOR THE TREATMENT OF SEVERE HYPOGLYCEMIA
UY35033A (en) FORMULATION IN TABLETS OF A 3-CINASA PHOSPHYTIDYLINOSITOL INHIBITOR